RecruitingPhase 1NCT05870579
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Studying Epidermal disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Intervention
- [68Ga]Ga-NeoB(drug)
- Enrollment
- 48 target
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2023 – 2032
Study locations (23)
- UCLA Jonsson Comp Cancer Center, Los Angeles, California, United States
- Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
- University of Kansas Medical Center, Westwood, Kansas, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Utah Intermountain Medical Center, Murray, Utah, United States
- Novartis Investigative Site, Guangzhou, China
- Novartis Investigative Site, Shanghai, China
- Novartis Investigative Site, Tianjin, China
- Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France
- Novartis Investigative Site, Bordeaux, France
- Novartis Investigative Site, Clermont-Ferrand, France
- Novartis Investigative Site, Saint-Herblain, France
- Novartis Investigative Site, Strasbourg, France
- Novartis Investigative Site, Cologne, North Rhine-Westphalia, Germany
- +8 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05870579 on ClinicalTrials.govOther trials for Epidermal disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07222215PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)Kristina A. Fanucci
- RECRUITINGPHASE1NCT07214662A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast CancerGenentech, Inc.
- RECRUITINGPHASE1, PHASE2NCT07049055A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic CancerEngeneic Pty Limited
- RECRUITINGPHASE1NCT07361237A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationsTongji University
- RECRUITINGPHASE2, PHASE3NCT07100080Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07216183Epidermal Sensors for Wireless and Enhanced Amputee Skin Tracking (E-SWEAT) Part 1North Carolina State University
- RECRUITINGPHASE3NCT06982521Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerRelay Therapeutics, Inc.
- RECRUITINGPHASE2NCT06348134Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After SurgeryUniversity of Chicago